Home LiteratureArticle Details
PMID: 19189403 Published · ppublish English Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

International journal of cancer ·Vol. 124 ·No. 11 ·2009-06-01 ·Pages 2683-9

Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J, Mucci LA

Abstract

Interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in prostate cancer patients, but the role of prediagnostic levels of these inflammatory mediators on prostate cancer outcomes is unclear. We undertook a large, prospective case-control study to evaluate the relation between prediagnostic levels of IL-6 and CRP and prostate cancer incidence and mortality. We also investigated the role of the IL-6 (-174 G/C) polymorphism in relation to circulating levels of IL-6 and CRP, as well as cancer risk and mortality. We used unconditional logistic regression that adjusted for matching factors to analyze prostate cancer risk. For analyses of prostate cancer mortality, we conducted survival analyses in cases. Because of the strong link between inflammatory markers and body mass index (BMI), we assessed interactions between BMI and plasma levels on prostate cancer outcomes. Neither IL-6 nor CRP plasma levels varied significantly by IL-6 genotype. Genotype was not associated with prostate cancer risk or survival. Though neither IL-6 nor CRP was associated with prostate cancer incidence overall, we observed a statistically significant interaction between IL-6 and BMI on prostate cancer incidence (p(interaction) < 0.01). Increasing IL-6 levels were positively associated with risk in healthy weight men, but inversely associated with risk in overweight men. Further, prediagnostic IL-6 was associated with time to prostate cancer progression/death among healthy weight prostate cancer cases (p(trend) = 0.02). Adjusted hazard ratios were 1.73 (95% CI: 0.86, 3.51) comparing the highest to lowest IL-6 level. Our study suggests that IL-6 may potentially be involved in the development or progression of prostate cancer.

MeSH Terms
Aged Body Mass Index C-Reactive Protein/analysis Case-Control Studies Double-Blind Method Genotype Humans Interleukin-6/blood,genetics Male Middle Aged Polymorphism, Single Nucleotide Prostatic Neoplasms/blood,epidemiology,mortality
Chemicals
Interleukin-6 C-Reactive Protein
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Stark Jennifer Rider
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. stark@hsph.harvard.edu
Li Haojie
Kraft Peter
Kurth Tobias
Giovannucci Edward L
Stampfer Meir J
Ma Jing
Mucci Lorelei A
References (35)
35 references, click to expand
  1. The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels.
    Haematologica. 2001 Feb;86(2):199-204 PMID: 11224491
  2. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease.
    Br J Cancer. 2004 Nov 15;91(10):1755-7 PMID: 15505624
  3. Adipose tissue as an endocrine and paracrine organ.
    Int J Obes Relat Metab Disord. 1998 Dec;22(12):1145-58 PMID: 9877249
  4. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density.
    Eur Urol. 2000 Apr;37(4):404-12 PMID: 10765070
  5. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
    Prostate. 1999 Oct 1;41(2):127-33 PMID: 10477909
  6. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
    J Urol. 2002 May;167(5):2267-70 PMID: 11956490
  7. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.
    Nat Genet. 2002 Feb;30(2):181-4 PMID: 11799394
  8. Interleukin-6 sequence variants are not associated with prostate cancer risk.
    Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1677-9 PMID: 15466986
  9. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.
    J Clin Endocrinol Metab. 1997 Dec;82(12):4196-200 PMID: 9398739
  10. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.
    N Engl J Med. 1996 May 2;334(18):1145-9 PMID: 8602179
  11. Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23.
    Hum Genet. 2003 Apr;112(4):414-8 PMID: 12594535
  12. Interleukin-6 polymorphism is associated with more aggressive prostate cancer.
    J Urol. 2005 Aug;174(2):753-6 PMID: 16006970
  13. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.
    Eur J Biochem. 1988 Nov 1;177(2):357-61 PMID: 3263918
  14. Interleukin-6: a candidate mediator of human prostate cancer morbidity.
    Urology. 1995 Mar;45(3):542-9 PMID: 7879350
  15. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer.
    Cancer Res. 2006 Apr 15;66(8):4525-30 PMID: 16618781
  16. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer.
    Prostate. 2004 Jun 1;59(4):393-400 PMID: 15065087
  17. Epidemiology of inflammation and prostate cancer.
    J Urol. 2004 Feb;171(2 Pt 2):S36-40 PMID: 14713751
  18. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
    Cancer. 2008 Jun;112(11):2377-83 PMID: 18428198
  19. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    J Urol. 1999 Jan;161(1):182-7 PMID: 10037394
  20. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer.
    Urol Int. 2006;77(2):127-9 PMID: 16888416
  21. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.
    Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 PMID: 16214925
  22. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group.
    Urology. 1999 Sep;54(3):467-72 PMID: 10475356
  23. Final report on the aspirin component of the ongoing Physicians' Health Study.
    N Engl J Med. 1989 Jul 20;321(3):129-35 PMID: 2664509
  24. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?
    BJU Int. 2003 Apr;91(6):545-53 PMID: 12656913
  25. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
    J Clin Oncol. 2006 Nov 20;24(33):5216-22 PMID: 17114654
  26. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.
    Eur Urol. 2003 Feb;43(2):164-75 PMID: 12565775
  27. Obesity, adipokines, and prostate cancer in a prospective population-based study.
    Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5 PMID: 16835332
  28. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
    Nat Genet. 2002 Oct;32(2):321-5 PMID: 12244320
  29. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    BJU Int. 2005 May;95(7):961-2 PMID: 15839913
  30. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.
    J Clin Invest. 1998 Oct 1;102(7):1369-76 PMID: 9769329
  31. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.
    Nat Genet. 2002 Dec;32(4):581-3 PMID: 12415269
  32. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
    Am J Hum Genet. 2003 Jan;72(1):208-12 PMID: 12471593
  33. Prospective study of sex hormone levels and risk of prostate cancer.
    J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26 PMID: 8757191
  34. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia.
    Urology. 2000 Nov 1;56(5):828-32 PMID: 11068311
  35. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms.
    Circulation. 2001 May 8;103(18):2260-5 PMID: 11342474
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
1097-0215
DOI
10.1002/ijc.24241
Email
stark@hsph.harvard.edu
Published
2009-06-01
Pages
2683-9
Language
English
Region
United States
NLM ID
0042124
PMCID
PMC2667697
Subset
IM
Grants
NHLBI NIH HHS · HL-34595 · United States
NHLBI NIH HHS · HL-26490 · United States
NCI NIH HHS · R01 CA058684-13 · United States
NHLBI NIH HHS · R01 HL034595 · United States
NCI NIH HHS · CA097193 · United States
NCI NIH HHS · T32CA009001-32 · United States
NCI NIH HHS · R01 CA058684 · United States
NCI NIH HHS · 5R01CA042182-20 · United States
NCI NIH HHS · T32 CA009001 · United States
NCI NIH HHS · 5R01CA058684-13 · United States
NCI NIH HHS · R01 CA040360 · United States
NCI NIH HHS · R01 CA034944 · United States
NCI NIH HHS · R01 CA042182 · United States
NHLBI NIH HHS · R01 HL026490 · United States
NCI NIH HHS · R01 CA097193 · United States
NCI NIH HHS · CA40360 · United States
External Links
PubMed source DOI: 10.1002/ijc.24241 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2